Pryor Cashman Represents CytoDel in Series A Financing
Pryor Cashman represented CytoDel, Inc. in connection with a private placement of Series A Convertible Preferred Stock to institutional accredited investors, led by a leading private equity fund that invests in significant scientific discoveries and supports them by providing capital and expertise. The offering closed on January 5, 2018.
CytoDel is a biopharmaceutical company that produces recombinant derivatives of botulinum neurotoxin, and engineers these derivatives to perform as molecular drug delivery vehicles, which can deliver therapeutic molecules to the inside of neurons. Delivering antibodies specifically to the neuronal cytoplasm without a viral vector has important implications for advancing the treatment of nervous system disorders, chronic pain and neurodegenerative diseases. CytoDel has also developed ways to utilize its discovery platform for musculoskeletal and aesthetic medicine.
The Pryor Cashman Team
Pryor Cashman has represented CytoDel in connection with all corporate matters since inception. Representing CytoDel in this transaction were Lawrence Remmel, Chair of the firm’s Banking + Finance Group, Partner Michael Dunworth, Counsel Michael T. Campoli and Associate Matthew T. Repetto.
